New white paper describes “Multiplex” strategy to achieve flexibility and scale in biopharmaceutical manufacturing
Vanrx Pharmasystems has released Manufacturing Injectables in the Multiplex, a white paper that describes a strategy to achieve flexibility and scale in biopharmaceutical manufacturing.
The white paper is available for download at www.vanrx.com/multiplex.
Multiplex manufacturing configures operations around smaller units of production and standard technologies that result in more flexible and cost-effective operations. The Multiplex model supports today’s reality of drugs with smaller target patient populations, uncertain market conditions and other factors.
“The companies that are adopting the Multiplex strategy are beating traditional supply chains in terms of cost of goods, time to market and quality,” says Chris Procyshyn, chief executive officer of Vanrx. “The pillars of the Multiplex are becoming a movement among the market leaders, so this is a must-read for executives looking to create a sustainable competitive advantage.”
Adopting a Multiplex strategy has a number of benefits, including:
- Reduced time to market;
- Maximizing the commercial potential of a multi-product portfolio;
- Agility to respond to market changes; and
- Effective and safe production of biologics for developing markets.
Vanrx was founded by experts in biopharmaceutical development and manufacturing. The company designs and manufactures Aseptic Filling Workcells—gloveless robotic isolators for producing vials, syringes and cartridges.
Attendees can pick up a copy of the Multiplex white paper at upcoming 2017 pharmaceutical industry events:
CPhI / P-MEC | Frankfurt, Germany | October 24-26 | Stand 4.0G64
ISPE Annual Meeting | San Diego, CA | October 29-31 | Stand 1414
CPhI / P-MEC India | Mumbai, India | November 28-30 | Hall 7A, Stand R27
ISPE Biopharmaceutical Manufacturing | San Francisco, CA | December 4-6
About Vanrx Pharmasystems
Vanrx Pharmasystems makes the most technologically advanced sterile filling solutions for the pharmaceutical industry. Vanrx fill-finish machines use isolated robotics and machine vision to automate the packaging of injectable drugs into nested vials, syringes, or cartridges. The company was founded by pharmaceutical industry veterans to create the systems needed to make the next generation of innovative therapies. For more information, visit www.vanrx.com.
To schedule interviews with Vanrx Pharmasystems CEO Chris Procyshyn or discuss future article contributions, please contact:
Senior Marketing Manager
Phone: +1.604.453.8660 ext. 773